E2F-1 has properties of a radiosensitizer and its regulation by cyclin A kinase is required for cell survival of fibrosarcoma cells lacking p53

Cell Growth and Differentiation

Volumn 10, Issue 3, 1999, Pages 141-146

  Pruschy, Martin ^a   Wirbelauer, Christiane ^b   Glanzmann, Christoph ^a   Bodis, Stephan ^a   Krek, Wilhelm ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; RADIOSENSITIZING AGENT; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; COMPLEX FORMATION; CONTROL SYSTEM; CYTOTOXICITY; DNA BINDING; ENZYME REGULATION; FIBROSARCOMA; IONIZING RADIATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; TRANSACTIVATION;

ANIMALS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; CELL SURVIVAL; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; FIBROSARCOMA; GENE EXPRESSION; GENES, P53; MICE; MICE, NUDE; PROTEIN KINASES; PROTEIN SYNTHESIS INHIBITORS; PUROMYCIN; RADIATION TOLERANCE; TIME FACTORS; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032992363     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Dyson, N. The regulation of E2F by pRB-family members. Genes Dev., 12: 2245-2262, 1998.
2. Helin, K. Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev., 8: 28-35, 1998.
3. Sellers, W. R., Rodgers, J. W., and Kaelin, W. G. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. USA, 92: 11544-11548, 1995.
4. Weintraub, S. J., Chow, K. N. B., Luo, R. X., Zhang, S. H., He, S., and Dean, S. C. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature (Lond.), 375: 812-815, 1995.
5. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
6. Xu, M., Sheppard, K. A., Peng, C. Y., Yee, A. S., and Piwnica-Worms, H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol., 14: 8420-8431, 1994.
7. Krek, W., Ewen, M. E., Shirodkar, S., Arany, Z., Kaelin, W. G., Jr., and Livingston, D. M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell, 78: 161-172, 1994.
8. Dynlacht, B. D., Flores, O., Lees, J. A., and Harlow, E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev., 8: 1772-1786, 1994.
9. SKP2 ubiquitin protein ligase and E2F-1 underlies regulation of E2F-1 degradation. Nat. Cell Biol., in press, 1999.
10. Singh, P., Wong, S., and Hong, W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J., 13: 3329-3338, 1994.
11. Xu, G., Livingston, D. M., and Krek, W. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc. Natl. Acad. Sci. USA, 92: 1357-1361, 1995.
12. Johnson, D. G., Ohtani, K., and Nevins, J. R. Oncogenic capacity of the E2F-1 gene. Proc. Natl. Acad. Sci. USA, 91: 12823-12827, 1994.
13. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. Expression of transcription factor E2F-1 induced quiescent cells to enter S phase. Nature (Lond.), 365: 349-352, 1993.
14. Qin, X-Q., Livingston, D. M., Kaelin, W. G., and Adams, P. Deregulated transcription factor E2F-1 expression leads to S phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA, 91: 10918-10922, 1994.
15. Shan, B. and Lee, W-H. Deregulated expression of E2F-1 induces S phase entry and leads to apoptosis. Mol. Cell. Biol., 14: 8166-8173, 1994.
16. DeGregori, J. L. G., Miron, A., Jakoi, L., and Nevins, J. R. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA, 94: 7245-7250, 1997.
17. Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev., 12: 2424-2433, 1998.
18. ARF links the tumour suppressors RB and p53. Nature (Lond.), 395: 124-125, 1998.
19. Kowalik, T. F., DeGregori, J., Leone, G., Jakoi, L., and Nevins, J. R. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ., 9: 113-118, 1998.
20. Kowalik, T. F., DeGregori, J., Schwarz, J. K., and Nevins, J. R. E2F-1 overexpression in quiescent fibroblasts leads to induction of DNA synthesis and apoptosis. J. Virol., 69: 2491-2500, 1995.
21. Wu, X., and Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
22. Phillips, A. C., Bates, S., Ryan, K. M., Helin, K., and Vousden, K. H. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev., 11: 1853-1863, 1997.
23. Nip, J., Strom, D. K., Fee, B. E., Zambetti, G., Cleveland, J., and Hiebert, S. W. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol. Cell. Biol., 17: 1049-1056, 1997.
24. Hsieh, J-K., Fredersdorf, S., Kouzarides, T., Martin, K., and Lu, X. E2F-1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev., 11: 1840-1852, 1997.
25. Krek, W., Xu, G., and Livingston, D. M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell, 83: 1149-1158, 1995.
26. Levine, A. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
27. Lowe, S. L., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-976, 1993.
28. Lowe, S. W., Bodis, S., McClattchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 806-810, 1994.
29. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
30. Samuelson, A. V., and Lowe, S. W. Selective induction of p53 and chemosensitivity in RB-deficient calls by E1A mutants unable to bind the RB-related proteins. Proc. Natl. Acad. Sci. USA, 94: 12094-12099, 1997.
31. Pear, W. S., Nolen, G. P., Scott, M. L., and Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA, 90: 8392-8396, 1993.
32. Krek, W., Livingston, D. M., and Shirodkar, S. Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members. Science (Washington DC), 262: 1557-1560, 1993.
33. Lisztwan, J., Marti, A., Sutterluety, H., Gstaiger, M., Wirbelauer, C., and Krek, W. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45SKP2: evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. EMBO J., 17: 368-383, 1998.